ArticleInfection and drug resistance2018
Carbapenem-resistant
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Prevalence of colistin resistance in clinical isolates ofFrontiers in microbiology · 2024Pooled it
- Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.PloS one · 2024Pooled it
- Epidemiological Study of the Relationship Between Antimicrobial Resistance Genes and Biofilm-Forming Capacity in Pathogens Causing Chronic Wound Infections.Microorganisms · 2026Article
- Alternative approaches in combating antimicrobial resistance in animals.Archives of microbiology · 2026Review
- Carbapenemase-mediated resistance in Acinetobacter baumannii clinical isolates: molecular epidemiology and antimicrobial potential of chitosan nanoparticles.BMC microbiology · 2026Article
- Mathematical modelling of synergistic triple-antibiotic therapy against carbapenem-resistantJournal of medical microbiology · 2025Article
- The enhanced antibacterial and antibiofilm properties of titanium dioxide nanoparticles biosynthesized by multidrug-resistant Pseudomonas aeruginosa.BMC microbiology · 2024Article
- Whole-genome sequencing of two multidrug-resistant acinetobacter baumannii strains isolated from a neonatal intensive care unit in Egypt: a prospective cross-sectional study.BMC microbiology · 2024Article
- Regulation of overexpressed efflux pump encoding genes by cinnamon oil and trimethoprim to abolish carbapenem-resistant Acinetobacter baumannii clinical strains.BMC microbiology · 2024Article
- An Update on Colistin in Clinical Healthcare Unit in the Kingdom of Saudi Arabia: A Narrative Review.Current pharmaceutical design · 2024Review
- Carbapenem Resistance inBioMed research international · 2024Article
- Design methods for antimicrobial peptides with improved performance.Zoological research · 2023Review
- Synergistic Antibiofilm Action ofMolecules (Basel, Switzerland) · 2023Article
- Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin.BMC microbiology · 2023Article
- Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
- Antimicrobial Resistance in Romania: Updates on Gram-Negative ESCAPE Pathogens in the Clinical, Veterinary, and Aquatic Sectors.International journal of molecular sciences · 2023Review
- Epidemiological, Microbiological, and Clinical Characteristics of Multi-ResistantTropical medicine and infectious disease · 2023Article
- Molecular characterization of multidrug resistantFrontiers in cellular and infection microbiology · 2023Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenamase producing PURPOSE: To characterize different carbapenemase genes carried by carbapenem-resistant (CR)
methodsCR
resultsGenes coding for OXA-23, NDM and GES were detected in 90, 66.7 and 50% of CR
conclusionCarbapenemase genes carriage accounts for high level carbapenem resistance in our isolates. Colistin/tigecycline and colistin/meropenem combinations can be considered for treatment of severe infections by CR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.